Sun Pharma Advanced Research Company Limited (SPARC)

216.78

INR
-2.68(-1.22%)
As of December 6, 2024 10:00:00 AM

Sun Pharma Advanced Research Company Limited Share Price Information

24 hour Low and High

Low: 215.49
High: 219.87

All time High

455.30

Price Change 1h

+₹-2.87 +-1.31%

Price Change 1d

+₹-2.87 +-1.31%

Price Change 1w

+₹19.40 +9.83%

Sun Pharma Advanced Research Company Limited Market Information

Exchange

NSE

Market Cap

7002.54 Cr

About Sun Pharma Advanced Research Company Limited Share

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

409

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • SPARC Q2 Results | Net loss widens to ₹107 crore, revenue dives 39% to ₹13 crore
  • Lower circuit stock: Sun Pharma Advanced share price tanks 5% on ending Proseek study; here's what analyst says | Stock Market News
  • Sun Pharma Advanced Research Company Limited's (NSE:SPARC) market cap rose ₹4.5b last week; private companies who hold 46% profited and so did insiders
  • Sun Pharma Advanced Research Company's Stock Faces Negative Outlook and Decline
  • Sun Pharma Advanced Research Reports ₹107.3 Crore Net Loss in Q2

FAQs

Sun Pharma Advanced Research Company Limited (SPARC)

216.78

INR
-2.68(-1.22%)
As of December 6, 2024 10:00:00 AM

Sun Pharma Advanced Research Company Limited Share Price Information

24 hour Low and High

Low: 215.49
High: 219.87

All time High

455.30

Price Change 1h

+₹-2.87 +-1.31%

Price Change 1d

+₹-2.87 +-1.31%

Price Change 1w

+₹19.40 +9.83%

Sun Pharma Advanced Research Company Limited Market Information

Exchange

NSE

Market Cap

7002.54 Cr

About Sun Pharma Advanced Research Company Limited Share

Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology, neurodegeneration, and Immunology. The company's products under development include Elepsia XR for the treatment of epilepsy; PDP-716 for the treatment of open-angle glaucoma; and Sezaby for the treatment of neonatal seizures. In addition, it is developing Vodobatinib (SCC-138), a c-ABL inhibitor, which is in phase 2 clinical trial to treat Parkinson's disease; has completed phase 1 clinical trial for the treatment of lewy body dementia; and in preclinical trial to treat alzheimer's disease. Further, the company develops Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. Additionally, it is developing SCD-153 for the treatment of alopecia areata and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India.

Sector

Healthcare

Drug Manufacturers - Specialty & Generic

Employees

about

409

CEO

Revenue (2023)

%

Country of Origin

India

Key Highlights

  • SPARC Q2 Results | Net loss widens to ₹107 crore, revenue dives 39% to ₹13 crore
  • Lower circuit stock: Sun Pharma Advanced share price tanks 5% on ending Proseek study; here's what analyst says | Stock Market News
  • Sun Pharma Advanced Research Company Limited's (NSE:SPARC) market cap rose ₹4.5b last week; private companies who hold 46% profited and so did insiders
  • Sun Pharma Advanced Research Company's Stock Faces Negative Outlook and Decline
  • Sun Pharma Advanced Research Reports ₹107.3 Crore Net Loss in Q2

FAQs